Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials.

Autor: Mantsios A; Public Health Innovation & Action, New York, NY, USA. amantsios@phiaconsulting.org., Murray M; ViiV Global Health Outcomes, London, England, UK., Karver TS; Johns Hopkins University, Baltimore, MD, USA., Davis W; George Washington University, Washington, DC, USA., Galai N; Johns Hopkins University, Baltimore, MD, USA., Kumar P; Georgetown University, Washington, DC, USA., Swindells S; University of Nebraska Medical Center, Omaha, NE, USA., Bredeek UF; Metropolis Medical, San Francisco, CA, USA., García RR; Hospital 12 de Octubre de Madrid, Madrid, Spain., Antela A; Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain., Gomis SC; ViiV Healthcare, Madrid, Spain., Bernáldez MP; GSK, Madrid, Spain., Czarnogorski M; ViiV Healthcare, Research Triangle Park, NC, USA., Hudson K; ViiV Healthcare, Research Triangle Park, NC, USA., Walters N; ViiV Healthcare, London, UK., Kerrigan D; George Washington University, Washington, DC, USA.

Publikováno v: BMC health services research [BMC Health Serv Res] 2021 Mar 20; Vol. 21 (1), pp. 255. Date of Electronic Publication: 2021 Mar 20.